Related Experiment Videos
[A case of subacute idiopathic interstitial pneumonia resistant to steroids, successfully treated with
Yuichi Ozawa1, Masaaki Ida, Takahumi Suda
1Department of Respiratory Medicine, Haibara General Hospital.
Abstract:
A 47-year-old woman was admitted to our hospital because of dry cough, fever, and subacute, progressive dyspnea. Chest radiography and computed tomography showed ground glass opacities in the lower lung fields. We suspected pneumonia caused by atypical pathogens and administered antibiotics, but they had no effect at all. Histopathologic findings from a transbronchial lung biopsy (TBLB) included intensive infiltration of mononuclear cells and edema on the alveolar wall with no evidence of fibrosis, fibroblasts, hyaline membrane, or granuloma. On the basis of these findings, we suspected interstitial pneumonia, but a surgical lung biopsy was not possible because the patient would not give her consent. After TBLB, corticosteroid was administered repetitively, but dyspnea was deteriorating as the ground glass opacities became more widespread, and tractional bronchiectasis appeared throughout the lung fields. Therefore, we decided to administer cyclophosphamide (CPA). This was very effective: all of her symptoms improved and the ground glass opacities and tractional bronchiectasis disappeared. Though we tapered and then discontinued corticosteroids a few months after CPA, there was no recurrence whatever. No signs suggesting the association of collagen vascular diseases were detected. The effectiveness of CPA in interstitial pneumonia associated with collagen vascular disease is occasionally reported, but the effect on idiopathic interstitial pneumonia, especially in acute and subacute progressive cases, is rarely reported. We think this is an interesting case to consider the availability of CPA in idiopathic interstitial pneumonia with subacute progression.
Insights
Cyclophosphamide (CPA) effectively treated a patient with subacute progressive idiopathic interstitial pneumonia. This immunosuppressive therapy resolved symptoms and imaging findings, with no recurrence after discontinuation.
Area of Science:
- Pulmonology
- Immunology
Background:
- Idiopathic interstitial pneumonia (IIP) presents with progressive dyspnea and ground-glass opacities.
- Standard treatments, including antibiotics and corticosteroids, were ineffective in this case.
Observation:
- A 47-year-old woman presented with subacute, progressive dyspnea, dry cough, and fever.
- Chest imaging revealed ground-glass opacities; transbronchial lung biopsy showed mononuclear cell infiltration and edema without fibrosis or granuloma.
Findings:
- Despite initial antibiotic and corticosteroid treatments, the patient's condition worsened with widespread opacities and tractional bronchiectasis.
- Administration of cyclophosphamide (CPA) led to significant clinical improvement, resolving all symptoms and radiographic abnormalities.
Implications:
- This case suggests cyclophosphamide may be a viable treatment option for severe, subacute progressive idiopathic interstitial pneumonia.
- Further research is warranted to explore CPA's efficacy in IIP, particularly in acute and subacute presentations.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF